Results 81 to 90 of about 23,301 (196)

Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase

Brazilian Journal of Medical and Biological Research, 2006
We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos, E.G. Rizzatti, A.B. Garcia, D.A.P. Gallo, R.P. Falcão   +4 more
doaj  

A rare case of breast carcinoma co-existing with axillary mantle cell lymphoma

World Journal of Surgical Oncology, 2003
Background Mantle cell lymphoma (MCL) is a rare variety of non-Hodgkin's lymphoma which originates from CD5+ B-cell population in the mantle zones of lymphoid follicles. Coexistence of such tumours in the axillary lymph nodes with invasive breast cancers
Scally John, Stafford Joanna A, Dutta Roy Subhajit, Selvachandran S N   +3 more
doaj   +1 more source

[Cytogenetics of mantle cell lymphoma].

Terapevticheskii arkhiv, 2004
To determine the type and rate of secondary chromosomal aberrations and role in pathogenesis of mantle cell lymphoma (MCL).Standard cytogenetic examination (SCE) and fluorescent in situ hybridization (FISH) with tests for 11q22/ATM, 13q14, 17p13/p53, 9p21/p16 and chromosome 12 centromere were made in 28 patients.Secondary chromosomal aberrations were ...
T N Obukhova, Yu Yu Lorie, L A Vodinskaya, G A Alimova, E A Nikitin, R S Samoilova, I В Kaplanskaya, E V Domracheva   +7 more
openaire   +2 more sources

MYC in Oncogenesis and Therapeutic Implications

MedComm, Volume 7, Issue 8, August 2026.
The MYC oncogene family (c‐MYC, N‐MYC, L‐MYC) functions as a central transcriptional hub orchestrating cancer progression through multiple interconnected pathways. This graphical abstract illustrates MYC's role as a multidimensional regulator positioned at the nexus of tumor microenvironment remodeling, metabolic reprogramming, and therapeutic ...
Na Zhang, Li Wei, Cuiping Tang, Peilong Lai, Wenbin Zhong, Hua You   +5 more
wiley   +1 more source

Synergy of NVP-BEZ235 and enzastaurin in mantle cell lymphoma

Clinical Management Issues, 2014
Mantle cell lymphoma (MCL) is a neoplasm classified as a B-cell malignancy, that accounts for approximately 3 to 8% of Non-Hodgkin’s lymphoma (NHL) cases diagnosed annually. MCL is difficult to treat and seldom considered cured.
Monica Civallero, Maria Cosenza
doaj   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Splenic lymphoid hyperplasia in a cat presenting with hyperammonaemia, hypercalcaemia and hypercobalaminaemia

Veterinary Record Case Reports, Volume 14, Issue 3, August 2026.
Abstract A 5‐year‐old, male neutered, Bengal‐cross cat presented with progressive neurological signs (ataxia and torticollis). Initial haematology, serum biochemistry and electrolytes (including calcium) were unremarkable; however, ammonia was markedly elevated.
Kerry E. Rolph, Tim Scase, Owen Davies
wiley   +1 more source

What Is Your Diagnosis? Blood Smear From a Mixed‐Breed Dog

Veterinary Clinical Pathology, EarlyView.
Laura S. Peres, Lina C. Bilhalva, Camila B. E. Mello, Abílio G. Silva, Andrea P. Santos, Stella F. Valle   +5 more
wiley   +1 more source

Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
A schematic summary of the population pharmacokinetic model of rituximab in treatment‐naïve Chinese DLBCL patients during induction therapy, along with key clinical implications. ABSTRACT This study aimed to establish and validate a population pharmacokinetic model for rituximab during induction therapy in treatment‐naive patients with diffuse large B ...
Wan‐Yi Zhou, Jing Ling, Meng‐Meng Guan, Ying Qu, Ying‐Hui Dan, Rong Chen   +5 more
wiley   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR‐T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT The tumour microenvironment (TME) of relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients is associated with resistance of DLBCL cells to CD19 CAR‐T cells. How to improve TME in DLBCL and improve the efficacy of CAR‐T cell therapy remains to be further explored.
Yao Qi, Xuemei Fan, Jia Wang, Xin Li, Juan Mu, Rui Cui, Qi Deng   +6 more
wiley   +1 more source